Compare Stocks

Date Range: 

 Translate BioC4 TherapeuticsAlloVirReplimune GroupREGENXBIO
SymbolNASDAQ:TBIONASDAQ:CCCCNASDAQ:ALVRNASDAQ:REPLNASDAQ:RGNX
Price Information
Current Price$18.53$33.20$22.02$34.79$34.21
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.61.41.51.51.6
Analysis Score4.33.53.53.53.4
Community Score1.83.13.32.42.7
Dividend Score0.00.00.00.00.0
Ownership Score1.70.00.01.71.7
Earnings & Valuation Score0.00.60.60.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$25.70$44.50$49.25$56.00$62.50
% Upside from Price Target38.69% upside34.04% upside123.66% upside60.97% upside82.70% upside
Trade Information
Market Cap$1.64 billion$1.41 billion$1.42 billion$1.65 billion$1.38 billion
Beta0.96N/AN/A2.631.28
Average Volume1,179,664275,756345,595384,831425,652
Sales & Book Value
Annual Revenue$7.80 millionN/AN/AN/A$35.23 million
Price / Sales178.72N/AN/AN/A41.27
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$2.56 per shareN/AN/A$5.01 per share$12.23 per share
Price / Book7.24N/AN/AN/A2.80
Profitability
Net Income$-113,290,000.00N/AN/A$-52,630,000.00$-94,730,000.00
EPS($1.84)N/AN/A($1.54)($3.26)
Trailing P/E RatioN/A0.000.00N/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-70.38%N/AN/AN/A-63.13%
Return on Equity (ROE)-27.54%N/AN/A-30.23%-21.73%
Return on Assets (ROA)-12.82%N/AN/A-24.66%-18.74%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.13%N/A
Current Ratio5.73%5.22%28.40%19.47%6.08%
Quick Ratio5.73%5.22%28.40%19.47%6.08%
Ownership Information
Institutional Ownership Percentage92.90%N/A32.07%55.79%75.23%
Insider Ownership Percentage12.30%N/A1.00%50.90%14.10%
Miscellaneous
Employees1229953122257
Shares Outstanding75.23 million43.19 million65.11 million46.49 million42.51 million
Next Earnings Date5/6/2021 (Estimated)6/10/2021 (Estimated)5/13/2021 (Estimated)6/2/2021 (Estimated)8/5/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
Regenxbio EPS beats by $0.02, misses on revenue - Seeking AlphaRegenxbio EPS beats by $0.02, misses on revenue - Seeking Alpha
seekingalpha.com - May 6 at 3:17 AM
Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo FinanceRegenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
finance.yahoo.com - May 6 at 3:17 AM
Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue EstimatesRegenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates
finance.yahoo.com - May 6 at 3:17 AM
Regenxbio Inc. (RGNX) Q1 2021 Earnings Call TranscriptRegenxbio Inc. (RGNX) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 6 at 3:17 AM
REGENXBIO Inc. (RGNX) CEO Ken Mills on Q1 2021 Results - Earnings Call Transcript - Seeking AlphaREGENXBIO Inc. (RGNX) CEO Ken Mills on Q1 2021 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 5 at 10:17 PM
Regenxbio: Q1 Earnings Snapshot - The Edwardsville IntelligencerRegenxbio: Q1 Earnings Snapshot - The Edwardsville Intelligencer
theintelligencer.com - May 5 at 10:17 PM
REGENXBIO Reports First Quarter 2021 Financial Results and Operational Highlights - PRNewswireREGENXBIO Reports First Quarter 2021 Financial Results and Operational Highlights - PRNewswire
prnewswire.com - May 5 at 5:16 PM
REGENXBIO Reports First Quarter 2021 Financial Results and Operational HighlightsREGENXBIO Reports First Quarter 2021 Financial Results and Operational Highlights
finance.yahoo.com - May 5 at 5:16 PM
Companies Like Replimune Group (NASDAQ:REPL) Can Afford To Invest In Growth - NasdaqCompanies Like Replimune Group (NASDAQ:REPL) Can Afford To Invest In Growth - Nasdaq
nasdaq.com - May 5 at 12:15 PM
Buy Or Fear REGENXBIO Stock: RGNXs 19% Decline In A Year Despite Revenues Increasing 339% YoY Over The Last 4 Quarters Looks Like A Buying Opportunity. The stock has lost 21% since the end of 2018 due to unfavorable Changes In Its Total Revenues - TrefisBuy Or Fear REGENXBIO Stock: RGNX's 19% Decline In A Year Despite Revenues Increasing 339% YoY Over The Last 4 Quarters Looks Like A Buying Opportunity. The stock has lost 21% since the end of 2018 due to unfavorable Changes In Its Total Revenues - Trefis
dashboards.trefis.com - May 5 at 12:15 PM
Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely? - NasdaqWill Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely? - Nasdaq
nasdaq.com - May 5 at 1:43 AM
(RGNX) - Preview: Regenxbios Earnings - Benzinga(RGNX) - Preview: Regenxbio's Earnings - Benzinga
benzinga.com - May 4 at 3:42 PM
What Is The Ownership Structure Like For REGENXBIO Inc. (NASDAQ:RGNX)? - NasdaqWhat Is The Ownership Structure Like For REGENXBIO Inc. (NASDAQ:RGNX)? - Nasdaq
nasdaq.com - May 4 at 3:42 PM
Global Hunter Syndrome Treatment Market 2025: Top Key Players GC Pharma, Takeda Pharmaceutical Company, RegenxBio Inc. and others – FLA News - FLA NewsGlobal Hunter Syndrome Treatment Market 2025: Top Key Players GC Pharma, Takeda Pharmaceutical Company, RegenxBio Inc. and others – FLA News - FLA News
flanewsonline.com - May 4 at 5:41 AM
Optogenetic Market By Size, Share, Trends, Forecast Analysis & Manufacturers – Addgene, Cobalt International Energy, Coherent, Laser Glow Technology, Jackson Laboratories, Regenxbio, Thorlabs – Clark County Blog - Clark County BlogOptogenetic Market By Size, Share, Trends, Forecast Analysis & Manufacturers – Addgene, Cobalt International Energy, Coherent, Laser Glow Technology, Jackson Laboratories, Regenxbio, Thorlabs – Clark County Blog - Clark County Blog
clarkcountyblog.com - May 3 at 10:46 PM
Adverum halt raises more gene therapy questions - VantageAdverum halt raises more gene therapy questions - Vantage
evaluate.com - April 29 at 12:53 PM
REGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational Highlights - Yahoo FinanceREGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational Highlights - Yahoo Finance
finance.yahoo.com - April 29 at 7:53 AM
REGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational HighlightsREGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational Highlights
finance.yahoo.com - April 29 at 1:21 AM
REGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational Highlights - Herald-Mail MediaREGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational Highlights - Herald-Mail Media
heraldmailmedia.com - April 28 at 8:21 PM
REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapys 24th Annual Meeting - PRNewswireREGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 24th Annual Meeting - PRNewswire
prnewswire.com - April 27 at 11:13 PM
REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapys 24th Annual Meeting - Yahoo FinanceREGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 24th Annual Meeting - Yahoo Finance
finance.yahoo.com - April 27 at 6:13 PM
REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapys 24th Annual MeetingREGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 24th Annual Meeting
finance.yahoo.com - April 27 at 6:12 PM
Metachromatic Leukodystrophy (MLD) Treatment Market Analysis, Market Size, Competitive Strategies, Forecasts to 2026 and Key Vendors: ArmaGen Inc, RegenxBio Inc, GlaxoSmithKline Plc, Recursion Pharmaceuticals Inc, More - Clark County BlogMetachromatic Leukodystrophy (MLD) Treatment Market Analysis, Market Size, Competitive Strategies, Forecasts to 2026 and Key Vendors: ArmaGen Inc, RegenxBio Inc, GlaxoSmithKline Plc, Recursion Pharmaceuticals Inc, More - Clark County Blog
clarkcountyblog.com - April 27 at 8:12 AM
Vaccines made from aborted fetus cells? Fargo firm aims to develop cell lines free of ethical concerns - West Central TribuneVaccines made from aborted fetus cells? Fargo firm aims to develop cell lines free of ethical concerns - West Central Tribune
wctrib.com - April 22 at 1:33 PM
Head to Head Analysis: REGENXBIO (NASDAQ:RGNX) & SQZ Biotechnologies (NYSE:SQZ)Head to Head Analysis: REGENXBIO (NASDAQ:RGNX) & SQZ Biotechnologies (NYSE:SQZ)
americanbankingnews.com - April 21 at 8:20 PM
DateCompanyBrokerageAction
3/29/2021Translate BioSVB LeerinkReiterated Rating
3/24/2021Translate BioTruist SecuritiesReiterated Rating
3/24/2021Translate BioEvercore ISIReiterated Rating
3/24/2021Translate BioHC WainwrightLower Price Target
3/24/2021Translate BioRoth CapitalLower Price Target
3/19/2021Translate BioWilliam BlairReiterated Rating
10/5/2020Translate BioThe Goldman Sachs GroupInitiated Coverage
8/19/2020Translate BioCitigroupLower Price Target
6/26/2020Translate BioSunTrust BanksInitiated Coverage
6/23/2020Translate BioJefferies Financial GroupBoost Price Target
3/31/2021C4 TherapeuticsBMO Capital MarketsInitiated Coverage
10/28/2020C4 TherapeuticsUBS GroupInitiated Coverage
4/26/2021AlloVirMorgan StanleyBoost Price Target
2/11/2021AlloVirPiper SandlerBoost Price Target
8/24/2020AlloVirJPMorgan Chase & Co.Initiated Coverage
1/7/2019AlloVirBank of AmericaUpgrade
11/17/2020Replimune GroupBTIG ResearchInitiated Coverage
10/15/2020Replimune GroupBarclaysBoost Price Target
10/14/2020Replimune GroupChardan CapitalBoost Price Target
6/3/2020Replimune GroupWedbushReiterated Rating
1/20/2021REGENXBIORoyal Bank of CanadaBoost Price Target
1/6/2021REGENXBIORaymond JamesUpgrade
(Data available from 5/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.